Schizophrenia is an often devastating neuropsychiatric illness whose etiology remains unknown despite considerable study. Genetic factors have been strongly and consistently implicated in its etiology. Currently, there are multiple positive and plausible findings, but no finding currently meets a rigorous but appropriate definition of proof. There is considerable uncertainty about which of the findings in the literature represent true findings upon which to build the next generation of schizophrenia research. Our goals are extremely ambitious but attainable. We wish to help research into the genetics of schizophrenia move to a solid empirical foundation that can withstand rigorous scrutiny. We have designed a well-functioning international collaboration to attain these aims: (1) We have identified ~29,000 cases via record linkage who could be contacted immediately. (2) We seek to biobank DMA samples from 7,500 cases with schizophrenia and 7,500 well-matched controls ascertained via high-quality Swedish national hospitalization and population registries. Both cases and controls will be population-based and of Scandinavian ancestry. Neurocognitive endophenotypes will be collected. (3) We will rigorously evaluate 10 candidate genes for schizophrenia. (3a) Following a comprehensive quantitative literature review, a pluralistic expert panel will select the 10 most promising genes. (3b) Genotype all cases and controls for 768 SNPs in these genes to capture genetic variation comprehensively, analyze, and with the expert panel select two genes for resequencing entire genomic transcripts for both common variants (N=48 cases, Aim 3c) and functional genomic regions for rare variants (N=1000 cases, Aim 3d). (3e) Complete the evaluation of these genes by conducting additional genotyping in cases and controls for SNPs identified in re-sequencing and finalize the analyses by investigating the relevance of neurocognition, birth insults (GxE interactions), family history (covariate indexing genetic risk), and age 18 conscription data (males only, possible endophenotypes) using prospective register data. A full-scale pilot study has proven that we can achieve these aims and strongly supports the validity of our assumptions. We have improved our diagnostic procedures and have shown that power will not be substantially altered by misclassification of either cases or controls. This research team is committed to collaborative """"""""open-source"""""""" genetic research. All phenotypes, genotypes, and DMA samples will be made available via the Kl BioBank. Application procedures will be straight-forward and require a brief page application that documents: a reasonable scientific plan, a timeline for completion and return of all unused samples, commitment to depositing all data created on these samples into a central repository at the Kl upon completion, and agreement to uphold the ethical and altruistic principles fundamental to this project. On the short-term, completion of this work will provide strong and possibly definitive evidence of the relevance of the best current set of 10 candidate genes for schizophrenia. For the long-term, establishment of this sample will provide an accessible resource for the psychiatric research community. Future projects could include whole genome association and nested case-control studies. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
1R01MH077139-01A1
Application #
7211122
Study Section
Behavioral Genetics and Epidemiology Study Section (BGES)
Program Officer
Lehner, Thomas
Project Start
2007-09-29
Project End
2010-05-31
Budget Start
2007-09-29
Budget End
2008-05-31
Support Year
1
Fiscal Year
2007
Total Cost
$2,545,278
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Martin, Alicia R; Karczewski, Konrad J; Kerminen, Sini et al. (2018) Haplotype Sharing Provides Insights into Fine-Scale Population History and Disease in Finland. Am J Hum Genet 102:760-775
Ganna, Andrea; Satterstrom, F Kyle; Zekavat, Seyedeh M et al. (2018) Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. Am J Hum Genet 102:1204-1211
Curtis, David; Coelewij, Leda; Liu, Shou-Hwa et al. (2018) Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology. Behav Genet 48:198-208
Magri, Chiara; Giacopuzzi, Edoardo; La Via, Luca et al. (2018) A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme. Sci Rep 8:15470
Rao, A R; Yourshaw, M; Christensen, B et al. (2017) Rare deleterious mutations are associated with disease in bipolar disorder families. Mol Psychiatry 22:1009-1014
Singh, Tarjinder; Walters, James T R; Johnstone, Mandy et al. (2017) The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet 49:1167-1173
Leonenko, Ganna; Richards, Alexander L; Walters, James T et al. (2017) Mutation intolerant genes and targets of FMRP are enriched for nonsynonymous alleles in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 174:724-731
Direk, Nese; Williams, Stephanie; Smith, Jennifer A et al. (2017) An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype. Biol Psychiatry 82:322-329
Singh, Tarjinder; Kurki, Mitja I; Curtis, David et al. (2016) Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci 19:571-7
Curtis, David (2016) Pathway analysis of whole exome sequence data provides further support for the involvement of histone modification in the aetiology of schizophrenia. Psychiatr Genet 26:223-7

Showing the most recent 10 out of 78 publications